Event Details Page

Date and Time10/19/2010 6:00 PM
NameHerceptin TLC Nursing Dinner Program
SpeakerJill Cooper
LocationJohn Howie Steak House
Click Register to register for this event

If you would like to register for a different event click here.

If you need assistance, please call our event specialists:


Telephone: (877) 282-4050

Fax: (888) 251-5650



Indications
Adjuvant indications
Herceptin is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature) breast cancer:

  • As part of a treatment regimen containing doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
  • With docetaxel and carboplatin
  • As a single agent following multi-modality anthracycline-based therapy
Metastatic indications
Herceptin is indicated:
  • In combination with paclitaxel for the first line treatment of HER2 overexpressing metastatic breast cancer
  • As a single agent for treatment of HER2 overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease
Boxed WARNINGS and Additional Important Safety Information Herceptin administration can result in sub-clinical and clinical cardiac failure manifesting as congestive heart failure and decreased left ventricular ejection fraction. Serious infusion reactions and pulmonary toxicity have occurred; fatal infusion reactions have been reported. Exacerbation of chemotherapy-induced neutropenia has also occurred. The most common adverse reactions associated with Herceptin use were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia.

Please click here for full prescribing information for Boxed WARNINGS and additional important safety information.